Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection

September 24, 2026 updated by: Jiangrong Wang, Karolinska Institutet

Risk of Cervical Cancer Following Incident, Persistent and History-unknown Human Papillomavirus (HPV) Detection by HPV Genotype

The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in HPV-based cervical screening. The main questions it aims to answer are:

  1. Whether an incident HPV detection with certain HPV genotypes has low risk of cervical cancer in 3 to 5 years thus does not need further clinical assessment before the next screening test?
  2. How risky a persistent HPV detection is, and whether persistent detection of any high-risk HPV genotype warrant immediate clinical assessment?
  3. How risky a HPV detection is, if no previous HPV test result is available?

As being a register-based retrospective observational study, study subjects will not be asked to do any specific task for this study.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study includes all women in the study population (women at screening ages and living in the Stockholm region during 2014-2023) who had HPV positive test result(s) in the primary HPV screening. In 2014-2016, half of the screening population were randomised to primary HPV screening and the other half received cytology-based screening (NCT01511328). From 2017 onwards, all women received primary HPV screening. As data are retrieved from established registries which are already accessible to the researchers for previous and ongoing related research projects, the data collection time is almost negligible.

Study Type

Observational

Enrollment (Estimated)

130000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Stockholm, Sweden, 141 52
        • Recruiting
        • Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Jiangrong Wang, PhD
        • Principal Investigator:
          • Joakim Dillner, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in the primary HPV test during 2014-2023

Description

Inclusion Criteria:

  • Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in primary HPV test during 2014-2023

Exclusion Criteria:

  • Women without valid personal identity number in the population registry

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Incident HPV detection

The first HPV positive result in the primary HPV test, following an HPV negative test result in the previous primary HPV test

All data will be retrieved retrospectively from registry data.

Persistent HPV detection

The HPV positive result in the primary HPV test following an HPV positive test result with the same genotype in the previous primary HPV test

All data will be retrieved retrospectively from registry data.

History-unknown HPV detection

The first HPV positive result in the primary HPV test, without any primary HPV test record in the past

All data will be retrieved retrospectively from registry data.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnosis of invasive cervical cancer
Time Frame: From HPV infection to the end of the study Dec 31st, 2024

Primary and invasive cervical cancer

From HPV infection to the end of the study Dec 31st, 2024

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Precancerous lesion CIN2+ (Cervical Intraepithelial Neoplasia grade 2 and above)
Time Frame: From HPV infection to the end of the study Dec 31st, 2024

CIN2, CIN3, Adenocarcinoma in situ

From HPV infection to the end of the study Dec 31st, 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2025

Primary Completion (Actual)

November 3, 2025

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

September 24, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IPUHPV&CxCa

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD will be derived from the Swedish National Cervical Screening Registry and the Swedish National Quality Register for Gynaecological Cancers. Data from these two registries can be shared upon application, provided that ethical approval is obtained.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.